approval · primary record
PEGCETACOPLAN
2 approval events · latest 2026-08-20
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-08-20 |
| Approval events | 2 |
| Brand | EMPAVELI |
| Sponsor | APELLIS PHARMS |
| Route | SUBCUTANEOUS |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-08-20 | FDA | NDA | EMPAVELI | APELLIS PHARMS | SUBCUTANEOUS |
| 2025-03-27 | FDA | NDA | SYFOVRE | APELLIS PHARMS | INTRAVITREAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:28:33.859Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:pegcetacoplan
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEGCETACOPLAN (APL-2) · trial
- Pegcetacoplan · trial
- Pegcetacoplan · compound